Holen Sie sich die Stockscreener-App
0.8864
3.15%
0.0271
Handel nachbörslich:
.89
0.0036
+0.41%
Schlusskurs vom Vortag:
$0.8593
Offen:
$0.8767
24-Stunden-Volumen:
112.81K
Relative Volume:
0.12
Marktkapitalisierung:
$114.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-4.0291
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
-0.58%
1M Leistung:
+10.84%
6M Leistung:
-5.59%
1J Leistung:
-40.11%
1-Tages-Spanne:
$0.8738
$0.8909
1-Wochen-Bereich:
$0.8388
$0.93
52-Wochen-Spanne:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8864 | 111.00M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
What drives Atossa Therapeutics Inc. stock priceBreakneck growth rates - Autocar Professional
Is Atossa Therapeutics Inc. a good long term investmentRapid wealth creation - jammulinksnews.com
What analysts say about Atossa Therapeutics Inc. stockTremendous wealth creation - jammulinksnews.com
Why Atossa Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser
Atossa Therapeutics Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com
Should I buy Atossa Therapeutics Inc. stock before earningsHigh Win Rate Stock Ideas - Newser
How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Atossa Therapeutics Inc. stock price move sharplyTrade With Low Risk Exposure - Newser
Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity - MSN
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com
Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq
Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada
Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus
Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener
Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus
Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):